TITLE

Lorcaserin: A novel antiobesity drug

AUTHOR(S)
Brashier, Dick B. S.; Sharma, A. K.; Navdeep Dahiya; Singh, S. K.; Anjan Khadka
PUB. DATE
April 2014
SOURCE
Journal of Pharmacology & Pharmacotherapeutics;Apr-Jun2014, Vol. 5 Issue 2, p175
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Obesity is a major co-morbidity with hypertension and diabetes mellitus. There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin. Lorcaserin has serotonergic properties and acts as an anorectic. It may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. Although, mainstay and first line of approach of treatment will always remain in having low calorie diet and increase in physical activity. Lorcaserin has come as a new hope to achieve success in treating obese patients but still a long road with further extensive research to be undertaken in the treatment of obesity.
ACCESSION #
95575327

 

Related Articles

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • ANOREXIGENIC DRUGS IN THE TREATMENT OF OBESITY: PAST, PRESENT AND FUTURE. ┼×tefania, Todea; Gabriel, Hancu // Acta Medica Marisiensis;2019 Supplement, Vol. 65, p69 

    Background: Obesity is a medical condition in which the subject carries an excess weight; and represents a great problem in modern society. Obesity is related to multiple reasons, including diet, lifestyle, pathological conditions, genetic factors or the use of certain medications. It can...

  • OBESITY DRUGS Not a Quick Fix.  // USA Today Magazine;Oct2000, Vol. 129 Issue 2665, p6 

    Provides information on the use of diet pills to reduce the weight of obese patients. Complications and side effects of diet pills; Benefits of diet and exercise therapy; Observation on the lifestyle of obese patients.

  • Current Concepts in the Pharmacological Management of Obesity. Carek, P.J.; Dickerson, L.M. // Drugs;Jun1999, Vol. 57 Issue 6, p883 

    The pharmacological management of obesity has gained increasing attention as new weight loss treatments are approved and a significant proportion of the public strives to lose weight. Obesity is associated with a high mortality rate, multiple chronic medical conditions, and carries an enormous...

  • orlistat. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p569 

    An encyclopedia entry for "orlistat" is presented. It refers to an anti-obesity drug used with a slimming diet for the treatment of severe obesity. It is different from appetite suppressants in that orlistat acts on the gastrointestinal tract, preventing the digestion of fats by lipases. The...

  • Why Diet Drugs Can Be Diet Dangers. Murphy, Dee // Current Health 2;Dec2000, Vol. 27 Issue 4, p18 

    Explains the dangers of using diet pills and other weight loss preparations. INSET: Why Diet Claims: Fact or Fiction?.

  • Fen-Phen `wannabe's' crowding the weight-loss scene. Zied, Elisa S. // Environmental Nutrition;Dec97, Vol. 20 Issue 12, p2 

    Evaluates several drugs for weight reduction. Need for prescription for the combination drug phentermine and fluoxetine; Herbal origins of the Herbal Phen-Fen drug alternative; Promotion of various amino acid combinations for weight loss uses.

  • New anti-obesity drug is not for everyone.  // Mayo Clinic Health Letter;Aug1999, Vol. 17 Issue 8, p4 

    Reports on the use of the anti-obesity drug orlistat. Indications approved by the United States Food & Drug Administration; Differences from other diet drugs; Side effects; Precautionary measures in using the drug.

  • Oxedrine.  // Reactions Weekly;4/3/2010, Issue 1295/1296, p30 

    The article describes the case of a 24-year-old man who developed ST elevation myocardial infarction (STEMI) while taking oxedrine for weight loss.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics